Twist Bioscience price target raised to $48 from $46 at Baird

Baird raised the firm’s price target on Twist Bioscience (TWST) to $48 from $46 and keeps an Outperform rating on the shares. The firm said they reported solid results with performance appearing to be broad-based, with modest revenue upside from each segment versus guidance. Baird continues to be encouraged by the synbio/NGS momentum, commentary around the Express portfolio, and broader GM% improvements and remain constructive on the setup into FY25.